GYKI-16084 is a postsynaptic alpha2-blocker. GYKI-16084 may be potentially useful for the treatment of benign prostatic hyperplasia. The combined alpha1- and postsynaptically selective alpha2-blocker GYKI-16084 significantly improved the AUA symptom scores and increased Q(max) in patients with BPH, without inducing any adverse reaction, orthostatic changes or erectile dysfunction. References:

纯度：≥98%

CAS：185739-21-3